Scientific Basis of Drug Therapy in Psychiatry (eBook)

Front Cover 1
The Scientific Basis of Drug Therapy in Psychiatry 4
Copyright Page 5
Table of Contents 8
EDITORS' NOTE 6
LIST OF PARTICIPANTS 10
INTRODUCTION 14
SESSION I: BASIC CONCEPTS 16
CHAPTER 1. ANATOMY AND PHYSIOLOGY OF THE EMOTIONS AND THEIR RELATION TO PYSCHOACTIVE DRUGS 18
PART I: NEUROANATOMICAL BASIS OF THE EMOTIONS 19
PART II: SITES OF ACTION OF PSYCHOPHARMACOLOGICAL DRUGS IN RELATION TO THE STRUCTURE OF THE LIMBIC SYSTEM 27
REFERENCES 38
CHAPTER 2. METHODS OF ASSESSMENT OF PSYCHOLOGICAL EFFECTS OF DRUGS IN ANIMALS 40
BASIC EXPERIMENTS 41
CONCLUSION 51
REFERENCES 51
CHAPTER 3. METHODS OF ASSESSMENT OF PSYCHOLOGICAL EFFECTS OF DRUGS IN MAN 54
INTRODUCTION 54
SELECTION OF PATIENTS 55
ASSESSMENT OF PSYCHOLOGICAL CHANGES 56
MEASURE OF IMPROVEMENT 57
REFERENCES 58
DISCUSSION 59
OPENER: A. SUMMERFIELD: 59
OPENER: IAN OSWALD: 61
REFERENCES 64
GENERAL DISCUSSION 65
REFERENCES 67
SESSION II: MAJOR TRANQUILLIZERS 68
CHAPTER 4. CLINICAL USE OF THE PHENOTHIAZINES 70
REFERENCES 76
CHAPTER 5. MODE OF ACTION OF THE PHENOTHIAZINES 78
BIOCHEMICAL ACTIONS OF THE PHENOTHIAZINES 79
THE FATE OF PHENOTHIAZINES IN THE BODY 81
THE EFFECT OF PHENOTHIAZINES ON THE TRANSPORT OF METABOLITES 82
THE TRANQUILLIZING ACTION OF THE PHENOTHIAZINES 83
REFERENCES 84
CHAPTER 6. STRUCTURE FUNCTIONAL RELATIONSHIPS WITHIN THE PHENOTHIAZINE CLASS 86
REFERENCES 92
CHAPTER 7. USE OF OTHER DRUGS IN THE TREATMENT OF THE SCHIZOPHRENIC 94
REFERENCES 103
DISCUSSION 105
OPENER: J. R. SMYTHIES: 105
REFERENCES 108
OPENER: K. RAWNSLEY: 108
REFERENCES 110
GENERAL DISCUSSION 111
REFERENCES 114
SESSION III: ANTIDEPRESSANTS 116
CHAPTER 8. SOME CLINICAL ASPECTS OF ANTIDEPRESSANT DRUGS 118
CLASSIFICATION 120
INDICATIONS AND USAGE 121
WHICH DRUG, WHICH PATIENT? 122
SIDE EFFECTS AND TOXIC EFFECTS 125
REFERENCES 128
CHAPTER 9. PHARMACOLOGY OF MONOAMINE OXIDASE INHIBITORS 130
1. EFFECTS ON MONOAMINE OXIDASE 131
2. PHARMACOLOGICAL EFFECTS IN ANIMALS 132
3. PSYCHOSTIMULANT EFFECTS IN HUMANS 138
REFERENCES 140
CHAPTER 10. SOME IDEAS ON THE MODE OF ACTION OF IMIPRAMINE-TYPE ANTIDEPRESSANTS 142
INTRODUCTION 143
PROOF THAT IMIPRAMINE ACTS THROUGH A METABOLITE 145
PROPERTIES OF DMI 147
OF THE MECHANISM OF ACTION OF DMI 151
SPECIES AND INDIVIDUAL DIFFERENCES 155
DISCUSSION 157
REFERENCES 161
DISCUSSION 162
OPENER: ALLAN C. TAIT: 162
REFERENCES 164
OPENER: PETER DALLY: 164
REFERENCES 166
GENERAL DISCUSSION 167
REFERENCES 169
SESSION IV: ANTI-ANXIETY COMPOUNDS 170
CHAPTER 11. USE OF DRUGS IN ANXIETY STATES 172
BARBITURATES 174
NEUROLEPTICS 175
RELAXANTS 175
REFERENCES 178
CHAPTER 12. MODE OF ACTION OF ANTI-ANXIETY COMPOUNDS 180
PHARMACOLOGICAL SCREENING PROCEDURES 182
OPERANT CONDITIONING PROCEDURES 183
ELECTROPHYSIOLOGICAL STUDIES 192
REFERENCES 192
DISCUSSION 194
OPENER: MAURICE PARTRIDGE: 194
REFERENCES 196
OPENER: E. BERESFORD DAVIES: 196
REFERENCES 199
GENERAL DISCUSSION 200
REFERENCES 202
SESSION V: GENERAL CONSIDERATIONS 204
CHAPTER 13. INTERACTIONS INVOLVING DRUGS USED IN PSYCHIATRY 206
REFERENCES 214
GENERAL DISCUSSION 217
CHAPTER 14. DRUG THERAPY IN PERSPECTIVE 220
CHAPTER 15. DESIGNATION OF COMPOUNDS AND THEIR CHEMICAL AND TRADE NAMES 222
INDEX 226